Medincell SA (MEDCL)
Euronext Paris · France · prices in EUR · close of 27 Oct 2026
Key indicators
| Last close | EUR 26.60 |
|---|---|
| 52-week range | 19.69 – 39.68 |
| Return, 1 month / 3 months | +15.6% / +2.3% |
| Return, 1 year / 3 years | −26.8% / +354.7% |
| Trend | Uptrend |
| RSI (14) | 55 |
| Volatility (1 year) | 56.5% |
| Worst drawdown (1 year) | -47.4% |
| Average daily value traded | 2.36M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Medincell is a pharmaceutical technology company based in France that develops long-acting injectable formulations of medicines. Its technology uses biodegradable polymers to release drugs slowly in the body over extended periods, aiming to improve how patients take their treatments. The company works with pharmaceutical partners to develop and commercialise products in areas such as mental health and infectious disease, and it earns revenue through licensing and collaboration agreements rather than from selling medicines directly to patients.
The shares are listed on the Euronext Paris in France under the code MEDCL, and the price on this page is in euros (EUR). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Medincell SA (MEDCL) trades on the Euronext Paris in France. It last closed at EUR 26.60 on 27 October 2026.
Its price-based Market X-Ray is 57 out of 100 (a fair price profile), ranking 256 of 625 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 26.8% and over the last three months it rose 2.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Paris
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 62 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 7.1% | ||
| From 52-week high | -30.8% | ||
| Momentum | 61 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 2.3% | ||
| 6-month return | 11.8% | ||
| 12-month return, skipping the last month | -36.6% | ||
| Stability (higher is calmer) | 32 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 56.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -47.4% | ||
| Liquidity | 84 · Strong | Trades actively. | |
| Average daily value traded | 2.36M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | −2.3% |
|---|---|
| 1 month | +15.6% |
| 3 months | +2.3% |
| 6 months | +11.8% |
| 1 year | −26.8% |
| 3 years | +354.7% |
| 5 years | +175.4% |
Signals
| 50-day / 200-day average | 24.26 / 24.85 |
|---|---|
| Golden / death cross (60 days) | Death, 32 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.44 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Paris; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.